Physician profile
Christopher Tipton
NPI 1750363685
$1,821.93
in general payments reported to CMS, 2019-2025
27 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $274 · 2022: $330 · 2023: $566 · 2024: $358 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,197 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,197.29 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.68 | 2021-2024 | Ofev |
| Abbvie INC. | $191.66 | 2023-2025 | |
| Amgen INC. | $110.45 | 2021-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $110.26 | 2022-2025 | Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $107.22 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Sumitomo Pharma America, INC. | $90.81 | 2023-2024 | Gemtesa |
| Novo Nordisk INC | $89.47 | 2024-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $84.31 | 2022-2025 | Fasenra, Airsupra, Breztri |
| Amarin Pharma, INC. | $82.32 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.53 | 2022-2025 | Aralast, Glassia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.93 | 2023-2024 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $63.06 | 2022-2023 | Eliquis |
| Daiichi Sankyo INC. | $54.74 | 2022-2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $48.52 | 2023-2024 | |
| Tactile Systems Technology INC | $47.64 | 2025 | Nimbl, Flexitouch Plus |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $38.71 | 2022-2023 | Yupelri |
| Lilly USA, LLC | $38.42 | 2024 | Jardiance |
| Esperion Therapeutics, INC. | $38.33 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $30.76 | 2022-2023 | Quviviq |
| Merck Sharp & Dohme LLC | $27.94 | 2021 | |
| Novartis Pharmaceuticals Corporation | $22.10 | 2022 | |
| Baxter Healthcare | $20.43 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Horizon Therapeutics Plc | $18.64 | 2022 | |
| Dexcom, INC. | $16.36 | 2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $14.46 | 2023 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.25 | 2025 | Caplyta |
| Athena Bioscience, LLC | $3.93 | 2024 | Nexiclon Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Tipton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.